$ALM

Almonty Industries ALM Stock Rallies On Tungsten Breakout

Almonty Industries (NASDAQ: ALM) stock rose 11.09% on positive tungsten market news and project progress. The company reported $42.99M in quarterly revenue, $1.22B in cash, and a share buyback plan. ALM secured inspection certificates for its Sangdong project in South Korea and expanded operations in Rwanda, positioning itself as a key tungsten supplier outside China.

Original reporting
Published Sep 25, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 5:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Almonty Industries ALM Stock Rallies On Tungsten Breakout — source image
Decision brief

The 30-second read

$ALMBullishMed
01

Why it matters

The new operational certifications and off‑take agreements provide concrete revenue visibility, while the $300M buyback indicates strong balance‑sheet confidence, together forming a catalyst for short‑term price appreciation.

02

Market read

The news provides a fresh, material catalyst for ALM's stock, likely influencing traders focused on critical‑minerals and small‑cap momentum plays.

03

What to watch

Potential geopolitical risks in Rwanda and commodity price volatility could temper upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Almonty Industries (NASDAQ: ALM) is a critical‑minerals miner focusing on tungsten production with projects in South Korea, Portugal, Spain, and now Rwanda.

Company-level read

Ticker impact

$ALMBullishHigh confidence
Context

Almonty Industries announced inspection certificates for full commercial operation at Sangdong, a new long‑term offtake deal, a Rwanda joint‑venture, and board‑approved $300M buyback, driving an 11% intraday rally.

Expected impact

Potential continuation of the rally if execution proceeds; watch for breakout above $13.85.

Evidence & confidence

New operational milestones and capital allocation are primary disclosures that materially affect valuation and short‑term price action.

Market effects

Highlights growing demand for non‑Chinese tungsten, potentially benefiting other critical‑minerals producers.

Strengthens exposure to Asian and African mining sectors, especially South Korea and Rwanda.

Adds to broader narrative of supply diversification in strategic minerals.

Counterpoint

If execution delays at Sangdong or Rwanda, the rally could reverse; high leverage remains a risk.

Key entities

  • Almonty Industries Inc.

    Tungsten miner reporting operational milestones and buyback.

  • Global Tungsten & Powders

    Long‑term offtake partner for Almonty.

  • Rwandan Government

    Joint‑venture partner for new tungsten concession.

Related articles

$ALMMed

Defense Stockpile Orders Send Explorers Back to Old Tungsten Camps

The U.S. Defense Logistics Agency awarded a $2B contract for tungsten supplies, with a $450M investment from the Department of War. GoldHaven Resources (CSE: GOH) completed drilling at its Kuhn tungsten-skarn target, intersecting skarn mineralization in two locations. Almonty Industries (NASDAQ: ALM) began commercial operations at its Sangdong plant, with 90% of Phase I production contracted. Guardian Metal (NYSE: GMTL) reported drilling results from its Tempiute project.

$ELMTMed

Technology Metals Report (10.04.2026): A Summit Without a Rare Earth Deal Leaves the West Buying Its Way to Supply

The U.S. and China failed to reach a rare earth supply deal during Xi Jinping's visit, leaving the West to secure supplies. Rare earth exports from China to the U.S. declined, with prices showing mixed trends. Elmet Group and Almonty Industries are expanding tungsten production. Glencore will partner with the U.S. strategic minerals reserve. Eramet plans to expand lithium production in Argentina. Processing capacity is also increasing, with Korea Zinc planning a U.S. smelter.

$ALMMed

Almirall, S.A.: Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026

Almirall, S.A. (ALM) presented new clinical data at EADV 2026, showcasing advances in dermatology treatments. Key findings include sustained improvements in atopic dermatitis with lebrikizumab and benefits in psoriasis with tildrakizumab. The company also highlighted its commitment to medical dermatology through sponsorship and awareness campaigns.

$ALMHigh

Why is Almonty Industries stock rallying today?

Almonty Industries (ALM) stock rose 2.7% in pre-market trading to $12.74. Stifel initiated coverage with a Buy rating and $25 target, while Goldman Sachs gave a Neutral rating and $13 target. The company's Sangdong mine in South Korea received final certification for commercial operations, securing 90% of Phase I output under long-term agreements. The S&P 500, Dow Jones, and Nasdaq were up 0.3%, 0.3%, and 0.5% respectively.